Clover Health Investments, Corp.

NASDAQ:CLOV

Medical - Healthcare Plans

Healthcare
$4.17 +3.54%

+$0.17 today

Market cap
$2.21B
Beta
2.48
P/E (TTM)
-45.6
EPS (TTM)
-$0.11
52W Low $1.58High $5.18

Volume 8.05M

Average 7.31M

CLOV Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Clover Health Investments, Corp.NASDAQ: CLOV

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How CLOV compares with its peers on the latest reported figures

  • CLOV's LTM Jun 2026 research & development of $0 is the highest of the 7 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CLOV, versus a peer median of 0.0%.
CLOV Competitors Peer median
Research & Development for CLOV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLOVClover Health Investments, Corp.LTM Jun 2026$0 ——0.0%
CVSCVS Health CorporationLTM Jun 2026$0 ——0.0%
CICigna CorporationLTM Sep 2026$0 ——0.0%
HUMHumana Inc.LTM Sep 2026$0 ——0.0%
CNCCentene CorporationLTM Jun 2026$0 ——0.0%
OSCROscar Health, Inc.LTM Jun 2026$0 ——0.0%
ALHCAlignment Healthcare, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding CLOV) $0——0.0%

Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.47B1.1B1.26B1.37B1.92B
Cost of Revenue1.55B993.07M1B1.01B1.57B
Gross Profit(79.18M)103.48M255.95M364.8M355.88M
Gross Margin-5.4%9.4%20.3%26.6%18.5%
Research & Development00000
Selling, General & Admin445.75M482.4M440.25M408.93M176.32M
Operating Expenses557.81M390.14M461.28M410.55M441.43M
Depreciation & Amortization1.25M1.19M2.51M1.33M1.69M
EBITDA(569.6M)(252.03M)(207.63M)(44.94M)(83.86M)
EBITDA Margin-38.7%-23.0%-16.5%-3.3%-4.4%
Operating Income(636.99M)(286.66M)(205.33M)(45.75M)(85.53M)
Operating Margin-43.3%-26.1%-16.3%-3.3%-4.4%
Interest Income00000
Interest Expense16.91M1.36M7K00
Other Income / Expenses49.24M32.08M(4.82M)(517K)(20K)
Income Before Tax(587.76M)(254.58M)(210.15M)(46.27M)(85.55M)
Pre-Tax Margin-39.9%-23.2%-16.7%-3.4%-4.4%
Income Tax Expense00000
Net Income(587.76M)(339.57M)(213.36M)(43.01M)(85.55M)
Net Margin-39.9%-31.0%-16.9%-3.1%-4.4%
EPS (Basic)(1.25)(0.71)(0.45)(0.09)(0.17)
EPS (Diluted)(1.25)(0.71)(0.45)(0.09)(0.17)
Weighted Avg Shares470.85M476.24M482.18M490.02M517.24M
Weighted Avg Shares (Diluted)470.85M476.24M482.18M490.02M517.24M

Clover Health Investments, Corp.

NASDAQ:CLOV

Intrinsic Alpha fair value

Locked

Current Price

$4.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.